// App-Quantinova.ai

BSH19‐PO‐077 : Efficacy and Safety of Single‐Agent Quizartinib (Q), Potent and SeleEfficacy and Safety of Single‐Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3‐Internal Tandem Duplication (FLT3‐ITD)–Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM‐R Trial

Researchers

Presenter

  • J.E. Cortes

Principal Investigators

  • G. Martinelli

  • A.E. Perl

  • S. Ganguly

  • N.H. Russell

  • A. Kramer

  • H. Dombret

  • D. Hogge

  • B.A. Jonas

  • A.Y.-H. Leung

  • P. Mehta

  • P. Montesinos

  • M.P. Radsak

  • S. Sica

  • M. Arunachalam

  • M. Holmes

  • K. Kobayashi

  • R. Namuyinga

  • N. Ge

  • A. Yver

  • Y. Zhang

  • M.J. Levis

Medical Centers

  • Department of Leukemia, University of Texas, Houston

  • City of Hope National Medical Center, Duarte, United States,

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • University of Pennsylvania, Philadelphia, PA

  • University of Kansas, Westwood, United States

  • Nottingham City Hospital, Nottingham, United Kingdom

  • University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany

  • University Paris-Diderot, UMRS-, Saint-Louis Hospital, Paris, France

  • Vancouver General Hospital, Vancouver, BC, Canada

  • University of California, Davis Comprehensive Cancer Center, Sacramento, CA

  • The Chinese University of Hong Kong, Hong Kong, Hong Kong

  • University of Bristol, Bristol, United Kingdom

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy

  • Daiichi Sankyo, Basking Ridge, NJ

  • Daiichi Sankyo, Basking Ridge, NJ

  • Sidney Kimmel Cancer Center at Johns Hopkins,Baltimore,United States

Locations

  • United States

  • Italy

  • United Kingdom

  • Germany

  • France

  • Canada

  • Hong Kong

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • C-C Motif Chemokine Ligand 28

  • Fms related tyrosine kinase 3

Drug/Treatment

  • Mitoxantrone

  • Midostaurin

  • fludarabine tablet

  • quizartinib

  • Cytarabine liposomal

  • Idarubicin Hydrochloride

  • Etoposide

  • Etoposide phosphate

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT02039726

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved